On the 10th, domestically produced vaccines came out with great news again, and netizens all gave thumbs up when they saw it, calling "Nice"!
Hundreds of thousands of new crown inactivated vaccines currently have zero infections
According to reports, in an interview with the media on the emergency use of the new crown inactivated vaccine and overseas phase III clinical research, the head of Sinopharm China Biotechnology revealed that the two new crown inactivated vaccines developed by Sinopharm Sinopharm have been used urgently and have been vaccinated hundreds of thousands of times. , There was no obvious adverse reaction, and no one was infected; among them, tens of thousands of people who went to overseas high-risk countries and regions after the vaccine had achieved zero infection so far.
Zhou Song, the general counsel of Sinopharm China Biotechnology, said that there are three domestic new crown inactivated vaccines approved for clinical trials, and Sinopharm China Biotechnology accounts for two of them. At present, it is also the largest emergency vaccination and the largest number of people, with hundreds of thousands of shots. There was no obvious adverse reaction or infection.
Zhou Song emphasized that the more important thing is that the emergency use of the new crown inactivated vaccine is aimed at people with high risk exposures, such as medical staff in medical institutions who treat patients with new crown infection, diplomats and foreigners who go to high-risk countries. Send employees, Chinese-funded enterprises "Belt and Road" construction personnel, etc. After these tens of thousands of people have been vaccinated, they have been overseas for a few months. They have a parallel control overseas, which means that there is a regional outbreak overseas. They vaccinated and went there to compare with the left-behind local employees. , A left-behind employee was infected, but he did not. Parallel control data like this is available in many countries, especially the tens of thousands of people who went to overseas high-risk countries and regions after the vaccine had achieved zero infection, which proved the effectiveness of the vaccine.
Zhang Yuntao, vice president of Sinopharm China Biology, said that phase I and II clinical studies of the new crown inactivated vaccine were conducted in China, and neutralizing antibodies were produced. "Neutralizing antibody testing is the gold standard." In overseas Phase III clinical studies, neutralizing antibodies will also be continuously observed. Neutralizing antibodies are comparable. Overseas trials have expanded races, countries, and populations, and most importantly, they have been recognized overseas, which will be better for future applications.
He said, it was difficult for our vaccines to be exported before, and there were a series of regulatory and clinical restrictions. Now our scientific and technological strength is strong, the phase I and II clinical trial data are recognized overseas, and the direct development of phase III clinical research overseas is a model of international cooperation. In the future, China's approval will be approved. As long as these countries have done these clinical studies, they can also be legally listed on the market. He revealed that at present, there is an intention of 500 million doses of the new crown inactivated vaccine internationally.
When will the new crown inactivated vaccine be launched?
Zhou Song said that at present, the production of the new crown inactivated vaccine of the Beijing Institute of Biological Products of Sinopharm Group has passed the joint biosafety inspection organized by the relevant departments and has the conditions for use. Sinopharm Group has invested about 2 billion yuan to build two high-level biosafety production workshops. Inactivated vaccines will be available as early as the end of December.
What is the price of the new crown inactivation after it is listed?
Zhang Yuntao said that the vaccine price will definitely be significantly lower than 1,000 yuan in general, but the price has not been set yet. In the future, two or three injections will depend on the test results. If it is two needles, it is possible to strengthen one needle in half a year or a year. This possibility is the greatest.
How long does it take for the vaccine to produce antibodies?
Zhou Song said that how long the vaccine can produce antibodies is also related to the immunization program. A total of two doses of the new crown inactivated vaccine are required, with an interval of 2 to 4 weeks. After the first dose, studies have shown that antibodies are generally produced within 7 days. After 28 days after the second dose, the neutralizing antibody positive conversion rate or The positive rate is 100%, that is, 28 days after receiving two doses of the vaccine according to the standardized immunization program, all people have produced high-titer antibodies that are sufficient to resist the new coronavirus.
How long will the new crown vaccine protect us?
Zhou Song said that there are several different versions and sayings. For example, the first version and the statement said that the antibody disappeared within 3 to 6 months in the body. Our company has also made it public to the society. The first person who took the vaccine was called the "180 vanguards who tried the medicine." It has been five or six months since the first vaccine was given. They are constantly drawing blood to monitor its health. The antibody value is still in the stable period of the antibody peak and has not declined, so the first statement is self-defeating. The second argument is more optimistic. Is it possible to have lifelong immunity? It's like getting a vaccinia vaccine when I was a child, and I won't live with smallpox. Now this possibility is not too great. At present, based on animal experiments, phased research results, and previous similar technology platform vaccines, it is estimated that the durability of immunity and the protective effect are likely to be more than 1 to 3 years.
However, on the 9th local time, the U.S. public health news website STAT reported that a high-profile British new crown vaccine suspended its Phase III clinical trial due to suspected serious adverse reactions in a vaccine subject.
It is reported that this vaccine was funded by the US government and was jointly developed by Oxford University and the British pharmaceutical giant AstraZeneca.
AstraZeneca stated in a statement that the company has initiated a standard review process and suspended vaccination to allow review of safety data. In addition, the company will shelve the research process.
A person familiar with the matter disclosed that the subject is expected to recover, but the nature of the adverse reaction and the time of its occurrence are unclear.
It is said that this is the second time that a subject has experienced symptoms in the vaccine clinical trial.
STAT reports that there are currently 9 candidate vaccines in the world that have entered the phase III trial stage. The vaccine developed by AstraZeneca is the first known vaccine whose clinical trials have been suspended.
According to Politico, the AstraZeneca vaccine is one of several vaccines supported by Trump's "Operation Warp Speed" program, which aims to accelerate the development of a new crown vaccine.
The Trump administration has agreed to fund 1.2 billion U.S. dollars for the AstraZeneca vaccine project and has ordered 300 million doses of vaccine in advance. Earlier, the US Consumer News and Business Channel (CNBC) stated in a report that the Trump administration had considered granting emergency use of the vaccine to AstraZeneca before election day so that it could be used in the United States.
It is reported that if the vaccine can be used before the election, it is enough to prove that the Trump administration, which has faced widespread doubts, has the ability to deal with the new crown epidemic.
It is reported that the Phase III clinical trials of the AstraZeneca vaccine are being conducted in the United States, the United Kingdom, Brazil and South Africa at the same time to determine the safety and effectiveness of the vaccine.
At present, these studies have been suspended as the independent committee initiated the verification of the company's vaccine safety.
Source: Chemical Network
